Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

CEL SCI CORP (CVM) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/10/2017 BW CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results
02/09/2017 BW CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results
08/18/2011 BW CEL-SCI Addresses Warning Letter in Regard to Statements on Its Corporate Website
07/19/2011 BW CEL-SCI Corporation and Teva Pharmaceuticals Expand Licensing Agreement
06/27/2011 BW CEL-SCI Announces Start of Multikine Phase III Study by Teva Pharmaceuticals Industries, Ltd. in Israel
05/26/2011 BW CEL-SCI Corporation Study Shows LEAPS Dendritic Cell Therapy to Be Effective in Treating H1N1 Virus
05/17/2011 BW CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Canada
05/16/2011 BW CEL-SCI Corporation Reports Second Quarter 2011 Financial Results
04/29/2011 BW CEL-SCI Corporation Receives Final Canadian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
04/28/2011 BW CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in India
04/13/2011 BW CEL-SCI Corporation's Chief Scientific Officer to Present Data Supporting Innovative Treatments for Cancer at World Vaccine Congress on April 14th
04/07/2011 BW CEL-SCI Corporation Receives Government Approval in India to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
03/30/2011 BW CEL-SCI Corporation Receives Israeli Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
02/11/2011 BW CEL-SCI to Present at 13th Annual BIO CEO & Investor Conference
02/10/2011 BW CEL-SCI Corporation Reports First Quarter 2011 Financial Results
12/15/2010 BW CEL-SCI Corporation Receives Government Approval from Ukraine to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
12/13/2010 BW CEL-SCI Corporation Announces Fiscal 2010 Financial Results
12/08/2010 BW CEL-SCI Corporation's Manufacturing and Laboratory Operations Deemed Compliant with GMP Requirements Following Audit by European Union Qualified Person
11/22/2010 BW CEL-SCI Completes Global Investigator Meeting in Preparation for Enrollment and Treatment of Patients in Phase III Head and Neck Cancer Trial
11/01/2010 BW CEL-SCI Corporation Receives $733,437 Grant Under the Patient Protection and Affordable Care Program
10/20/2010 BW CEL-SCI Corporation Receives Approval from Seven Hospital Institutional Review Boards in India to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
10/12/2010 BW CEL-SCI Corporation Receives Approval from First Taiwanese Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
09/27/2010 BW CEL-SCI Corporation Receives Russian Federation Ethical Council Approval for Multikine Phase III Clinical Trial in Head and Neck Cancer
09/13/2010 BW CEL-SCI Corporation Receives Approval from North Mississippi Health Services' Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
08/16/2010 BW CEL-SCI Corporation Reports Third Quarter 2010 Financial Results
05/17/2010 BW CEL-SCI Corporation Reports Second Quarter 2010 Financial Results
05/12/2010 BW CEL-SCI to Present at the 6th Annual Rodman and Renshaw Global Healthcare Conference

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy